Rusty M.

OH LA 2E CHUTE DE SEPP KUSS ! L'Américain se fait cette fois dépasser par Richard Carapaz ! #TDF2026

Win or lose, 3PM or 3AM, Thunder fans continue the playoff tradition of welcoming the team home:

Emergency officials have issued an EVACUATION WARNING at 13:25:28 on 02-28-2026 due to wildfire occurring in the area of Chatauqua Cottages. Visit BOCO911Alert.org for a map of the affected area and detailed information. More info to come

What’s the more tolerable temperature -2 or 102 with humidity

Golf hardos love to tell you that you shouldn't be playing blades. They fundamentally misunderstand why some of us play the game. Don't let em bully or shame you. #YOTB A column for our @fried_egg_golf newsletter. thefriedegg.com/articles/ror…

Today is Denver's 12th day this month with 60°+ temps. Zero doubt we'll break the record for most 60°+ days on record in December on record (15 days, 1980). #COwx

Pies ranked. 1. Cherry (if not too sweet). 2. Mixed berry. 3. Peach/blackberry. 4. Peach. 5. Apple. … 9. Key lime. … 99. Pecan. … 999. Pumpkin.

Dr. Naftali Kaminski is stepping down as @YalePCCSM section chief in 2026. Under his leadership, clinical programs, research funding & educational programs have expanded substantially in size, scope & impact. Learn more about @KaminskiMed & his tenure. medicine.yale.edu/internal-m…

We need to bring yellow back. The world has faded yellow.

At the 2025 @ARDD_Meeting , BioAge's SVP of Research @rmontonio presented our NLRP3 inflammasome inhibitor program, showcasing how structural biology and human longevity insights converge to create novel therapeutics. In his talk, Rusty described the discovery of structurally novel, highly potent NLRP3 inhibitors, and then shared exciting preclinical data showing that our lead inhibitor BGE-102 achieved weight loss comparable with injectable GLP-1 agonists—with additive effects in combination with semaglutide. A Phase 1 trial of BGE-102 was initiated in August, with top-line SAD data anticipated by end of year. Our NLRP3 program showcases how aging biology can unlock transformative approaches to metabolic disease. We were grateful for the opportunity to share this progress with the global geroscience community!

5 simple exercises to do before going to bed [📹 bboykilo]

Nothing but love for the Loud & Loyal that stayed up past 3:30 AM to welcome the squad home 🫶

The goal of legalized wagering was to bring bets from offshore grey and black markets into the regulated onshore space yet with every mind boggling decision from both regulators and politicians we continue to seemingly push money back offshore and take massive steps backward. It is simple: provide a good regulated environment for both bookies and bettors to operate and reap the rewards for a fantastic product offering and all the tax benefits/revenue that comes with it. However - greedy, illogical, and uneducated decisions from these folks have forced some sportsbooks out of business or to sweeps, lessened competition, made market access damn near impossible all for some short term tax gains that is going to burn out a-lot of the industry and its patrons. Hopefully things change although it doesn’t seem like we are headed in a positive direction when the decision makers at the top are all absolutely clueless (which is being kind).

We’re pleased to announce that BioAge is expanding our preclinical APJ agonist pipeline with highly potent oral small-molecule and injectable candidates designed to address key unmet needs in obesity treatment. APJ agonists are designed to mimic the effects of apelin, an exercise-induced signaling molecule known as an exerkine, which has been shown in preclinical studies to recapitulate many of the downstream benefits of exercise. Read the release: globenewswire.com/news-relea… Key developments • Antibody partnership: Secured option for JiKang Therapeutics’ novel APJ agonist nanobody with potency comparable to best-in-class small molecule APJ activators • New small molecule IP: Filed patents for novel oral APJ agonists with picomolar potency and excellent drug-like attributes • Dual modalities: Advancing both oral and injectable formulations to serve diverse patient preferences in the obesity market • Timeline: IND filing planned for 2026 Aging biology in action: BioAge’s discovery platform showed that people with higher circulating apelin levels live longer with better preserved physical function. Our preclinical data show that agonists of APJ, the apelin receptor, can mimic many of the benefits of physical activity, and have the potential to significantly increase GLP-1-driven weight loss while improving healthy body composition and muscle function. This represents a complementary mechanism that could improve weight loss efficacy, enhance tolerability, and promote healthier outcomes for patients on GLP-1 therapies. Excited to advance these next-generation approaches toward the clinic!

We’re happy to share that BioAge’s BGE-102—a potent, brain-penetrant, once-daily oral NLRP3 inhibitor—has completed IND-enabling studies and is advancing toward the clinic, with Phase 1 single-ascending-dose (SAD) data expected by year-end. Read the release: globenewswire.com/news-relea… Key points • Pharmacology: High potency and brain exposure support robust target engagement and a potential best-in-class profile. • Preclinical efficacy in obesity models:   ~15% weight loss as monotherapy (on par with semaglutide)    >20% when combined with a GLP-1 receptor agonist, demonstrating a strong additive effect • Formulation: Oral, once-daily dosing positions BGE-102 for a potential future incretin + NLRP3 combo pill. Aging biology in action NLRP3 is a key regulator of age-related chronic inflammation (“inflammaging”) that disrupts appetite control, metabolic health, and cardiovascular function. By inhibiting NLRP3, BGE-102 can help close the neuroinflammation gap left by current GLP-1 therapies and address a fundamental driver of aging biology. Beyond weight loss, NLRP3 inhibition has been associated with reductions in systemic markers such as CRP, suggesting broader cardiometabolic benefits for diverse patient populations. We look forward to sharing initial clinical data later this year!